BioSyent (BIOYF) Stock Price, News & Analysis

Company Overview

BioSyent Inc. is a specialty biopharmaceutical company focused on developing, manufacturing and commercializing pharmaceutical products and medical devices. The company leverages expertise in regulatory affairs, clinical development and manufacturing to deliver a range of branded and generic therapies across multiple therapeutic areas, with particular emphasis on endocrine disorders, supportive care oncology and dermatology.

BioSyent operates a manufacturing facility in Canada that supports both its proprietary portfolio and contract development and manufacturing services (CDMO) for small-molecule products. Its end-to-end capabilities—encompassing formulation, fill-finish and quality testing—serve clients in North America and selected international markets.

The company's commercial footprint spans Canada and the United States, where it markets specialty pharmaceuticals through its dedicated sales force and distribution partnerships. BioSyent continues to bolster its product pipeline through strategic in-licensing, acquisitions and targeted internal development programs, aiming to address evolving patient needs in niche therapeutic segments.

Guided by an experienced leadership team with backgrounds in pharmaceutical development and commercialization, BioSyent is focused on sustainable growth through portfolio expansion and manufacturing capacity enhancement. The company's strategy emphasizes high-value specialty products, positioning BioSyent to respond to emerging healthcare trends and regulatory opportunities.

Key Stats

• Today's Range: $10.00 to $10.09
• 50-Day Range: $9.81 to $11.00
• 52-Week Range: $7.63 to $12.00
• Volume: 1,151 shs
• Average Volume: 2,399 shs
• Market Capitalization: N/A
• P/E Ratio: 49.14
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BioSyent Stock Analysis - MarketRank™

BioSyent scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for BioSyent.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of BioSyent is 49.14, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.75.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioSyent is 49.14, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 24.21.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

BioSyent has a short interest ratio ("days to cover") of 0.19, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioSyent has recently increased by 89.62%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioSyent does not currently pay a dividend.

Dividend Growth

BioSyent does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Sentiment

BioSyent has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for BioSyent this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BioSyent insiders have not sold or bought any company stock.

Percentage Held by Institutions

0.08% of the stock of BioSyent is held by institutions.

Company Calendar

• Today: 6/14/2026
• Next Earnings (Estimated): 8/25/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:BIOYF
• CIK: N/A
• Web: www.biosyent.com
• Phone: (905) 206-0013
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 49.14
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A